It's a Chinese BTD?.... Your 2021 link: The sp
Post# of 148161
Your 2021 link:
The sponsor (Inventiva Pharma) designed the trial and monitored the trial sites, collected the data, and analyzed the data. All the authors had access to the data and reviewed the manuscript. The first and last authors and four of the authors employed by Inventiva Pharma participated in the analysis and interpretation of the data and vouch for the accuracy and completeness of the data and for the fidelity of the trial ...."
From 2022, 2023, 2024:
Some of the implemented changes include a reduction in the number of patient biopsies, a reduction in trial duration from seven years to 72 weeks, and potentially expanding the addressable patient population to include patients with NASH and compensated cirrhosis.
In September 2022, the company also licenced the therapy’s development and commercialisation rights in mainland China, Hong Kong, Macau and Taiwan to Sino Biopharm’s subsidiary, Chia Tia Tianquing Pharmaceutical (CTTQ).
Inventiva received $5m in milestone payments from CTTQ after investigational new drug (IND) approval from the Chinese National Medical Products Administration (NMPA) to initiate the clinical development in mainland China of lanifibranor in NASH, and the randomisation of the first patient.
https://www.clinicaltrialsarena.com/news/inve...;cf-closed